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Abstract
Background: Adiponectin acts as an antidiabetic, antiinflammatory and antiatherogenic adipokine.
These effects are assumed to be mediated by the recently discovered adiponectin receptors
AdipoR1 and AdipoR2.
Aim: The purpose of this study was to determine whether variations in the AdipoR1 and AdipoR2
genes may contribute to insulin resistance, dyslipidemia and inflammation.
Methods: We sequenced all seven coding exons of both genes in 20 unrelated German subjects
with metabolic syndrome and tested genetic variants for association with glucose, lipid and
inflammatory parameters.
Results: We identified three AdipoR2 variants (+795G/A, +870C/A and +963C/T) in perfect
linkage disequilibrium (r2 = 1) with a minor allele frequency of 0.125. This haplotype was associated
with higher plasma adiponectin levels and decreased fasting triglyceride, VLDL-triglyceride and
VLDL-cholesterol levels. No association, however, was observed between the AdipoR2 SNP
cluster and glucose metabolism.
Conclusion: To our knowledge, this is the first study to identify an association between genetic
variants of the adiponectin receptor genes and plasma adiponectin levels. Furthermore, our data
suggest that AdipoR2 may play an important role in triglyceride/VLDL metabolism.
Background
Adiponectin (also known as AdipoQ, APM1, and Acrp30)
is a hormone secreted by adipocytes that acts as an antid-
iabetic [1-5], antiinflammatory [6,7], and antiatherogenic
[8-10] adipokine. Plasma adiponectin levels are signifi-
cantly reduced in obesity, insulin resistance, metabolic
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syndrome, type 2 diabetes, and coronary heart disease
[11-17]. Plasma adiponectin concentrations are inversely
correlated with HOMA score, insulin levels, visceral and
total adipose tissue mass, plasma triglycerides, total and
LDL-cholesterol levels [18]. Conversely, adiponectin is
directly correlated with VLDL apoB catabolism and HDL-
cholesterol levels [18]. Molecularly, adiponectin was
shown to increase insulin sensitivity by enhancing insu-
lin's suppressive effect on glucogenesis [2,3] and by
increasing fatty acid oxidation in liver and skeletal muscle
through activation of AMP kinase and peroxisome prolif-
erator activated receptor (PPAR)-α [1,5,6]. Adiponectin's
antiinflammatory and antiatherogenic effects are thought
to be mediated by inhibition of TNF-α induced nuclear
factor-κB activation [19], inhibition of expression of
adhesion molecules [20], decreased smooth muscle cell
proliferation [8], and reduced foam cell formation [21].
Recently, two related but distinct receptors for adiponec-
tin were identified, termed adiponectin receptor 1
(AdipoR1) and adiponectin receptor 2 (AdipoR2) [22].
AdipoR1 was shown to be ubiquitously expressed,
whereas AdipoR2 expression is more restricted to skeletal
muscle and liver. In vitro overexpression and knockout
experiments demonstrated the receptors' ability to ligand-
dependently activate AMP kinase and PPAR-α, and to
stimulate fatty acid oxidation and glucose uptake in
murine hepatocytes and C2C12 myocytes [22]. Civitarese
et al. [23] reported that non-diabetic Mexican- American
subjects with a family history of type 2 diabetes exhibited
significantly lower levels of AdipoR1 and AdipoR2 mRNA
in skeletal muscle compared with those without a family
history. Expression levels of both receptors were positively
correlated with insulin sensitivity [23].
Assuming that adiponectin receptors AdipoR1 and
AdipoR2 mediate the antidiabetic and antiinflammatory
effects of adiponectin, we hypothesized that genetic varia-
tion in AdipoR1 and AdipoR2 may contribute to insulin
resistance, dyslipidemia, and inflammation. We
addressed this question by screening AdipoR1 and
AdipoR2 for genetic variants and testing for an association
between the observed sequence variation and glucose,
lipid, and inflammatory parameters in overweight, non-
diabetic, insulin resistant subjects.
Methods
Ascertainment of subjects
Twenty insulin resistant, abdominal overweight, unre-
lated German individuals were previously recruited for a
randomised, placebo-controlled, double-blind crossover
study to determine the effect of telmisartan, an angion-
tensin type-1 receptor blocker with PPAR-γ activating
properties, on glucose and lipid metabolism as well as
inflammatory parameters [24]. Insulin resistance was
defined as HOMA index ≥ 2.3. Subjects with manifest dia-
betes mellitus or secondary reasons for insulin resistance
(e.g. steroid therapy) were excluded. Abdominal over-
weight was defined as BMI ≥ 25 kg/m2, and waist circum-
ference of ≥ 95 cm in men or ≥ 80 cm in women,
respectively. Only subjects with a minimum blood pres-
sure of 120/80 mmHg were included. Subjects with a
known history of atherosclerosis (cerebrovascular, periph-
eral arterial, or coronary) as well as subjects with severe
hyperlipoproteinemia (defined as triglycerides >800 mg/
dl or LDL-cholesterol >190 mg/dl) were excluded. Other
exclusion criteria were a blood pressure of >160/95
mmHg, habitual alcohol consumption of >30 g/d, antihy-
pertensive medication, statin or lipid lowering therapy,
consuming illness, or a contraindication against the use of
angiotensin II receptor blockers. Subjects were ran-
domised to first receive placebo or telmisartan (40 mg/d)
for 12 weeks, after which they received the other medica-
tion (telmisartan or placebo). At screening and at the end
of each treatment phase primary and secondary parame-
ters were determined. Participating subjects were asked
not to change their dietary habits and physical activity
throughout the study. The Ethics Committee of the Lud-
wig-Maximilians-University Munich approved the study
protocol and all subjects gave written informed consent.
Determination of glucose and lipid metabolism 
parameters
Glucose metabolism was evaluated by fasting plasma glu-
cose (FPG), an oral glucose tolerance test (OGTT), and an
intravenous glucose tolerance test (iv GTT). Fasting values
included glucose, insulin, and C-peptide concentrations.
The OGTT was performed using 75 g glucose following a
12 h fast and was evaluated concerning the (incremental)
area under the curve defined by glucose concentrations
determined at 0, 30, 60, 90, and 120 min. To calculate the
(incremental) area under the insulin curve during OGTT,
insulin was also determined at 0, 30, 60, 90, and 120 min.
The intravenous glucose tolerance test was performed
using 25 g glucose. Both plasma glucose and insulin were
measured at 0, 2, 4, 6, 8, and 10 minutes after glucose
bolus application. The (incremental) area under the curve
for plasma glucose and for insulin was determined. First
phase insulin secretion, second phase insulin secretion,
insulin resistance index, and the composite index (Mat-
suda) were calculated based on the data derived from the
OGTT as previously described [25].
Triglyceride and cholesterol concentrations were meas-
ured using a commercial kit (Boehringer Mannheim,
Mannheim, Germany). Preparative ultracentrifugation
was performed to isolate VLDL. Cholesterol and triglycer-
ide concentrations were determined in the supernatant
and total cholesterol in the infranatant (containing LDL-
cholesterol and HDL-cholesterol). After precipitation ofCardiovascular Diabetology 2006, 5:11 http://www.cardiab.com/content/5/1/11
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apolipoprotein B-containing lipoproteins, HDL-choles-
terol was determined in the infranatant. LDL-cholesterol
was calculated by subtraction of HDL-cholesterol from
total cholesterol in the infranatant. Additionally, post-
prandial lipoprotein metabolism was evaluated using a
standardized oral fat tolerance test. After fasting for 12
hours all subjects ingested a fatty meal, consisting of 100
ml milk (3.5% fat), 150 ml cream (30% fat), 70 ml corn
oil, 90 g egg, 10 g sugar and 3.5 g coffee flavour. This
standard meal yields 1305 kilocalories, 87% from fat, 7%
from carbohydrates, and 6% from protein. Following the
fat load, samples were taken every 2 h for 10 h. Total trig-
lyerides and triglycerides in the d < 1.006 g/ml fraction
(containing chylomicrons, chylomicron remnants and
VLDL) were determined.
To elucidate possible effects on inflammatory processes,
high-sensitive (hs-) C-reactive protein (CRP) (Dade
Behring), interleukin-6 (IL-6) (R&D Systems), fibrinogen
(Dade Behring), and adiponectin (R&D Systems) concen-
trations were determined.
Identification of adiponectin receptor variants
Genotyping was performed on above described 20 unre-
lated subjects. Polymerase chain reaction (PCR) primers
for the seven coding exons of both adiponectin receptors
were selected in intronic sequence at least 50 base pairs
away from the intron/exon boundaries using VectorNTI
(Invitrogen). Genomic DNA was isolated from peripheral
blood leukocytes using the QIAamp DNA Blood Midi Kit
(Qiagen). PCR reactions containing 100 ng of DNA tem-
plate were amplified in a final volume of 25 µL by dena-
turation at 95°C for 5 minutes, followed by 35 cycles
(95°C for 45 seconds, 55°C for 45 seconds, and 72°C for
1 minute), and an extension at 72°C for 2 minutes. PCR
products were run on a 2% agarose gel, and, after confir-
mation of a single band with the expected size, were puri-
fied using the QIAquick PCR Purification Kit (Qiagen).
Purified fragments then underwent DNA cycle sequencing
using ABI PRISM Big Dye terminator chemistry (Applied
Biosystems) and appropriate sequencing primers.
Sequences were aligned using VectorNTI (Invitrogen) soft-
ware, and electropherograms were viewed using Chromas
Version 1.45 program. Allelic variations noted from mul-
tiple alignments were verified by inspecting the respective
electropherograms.
Statistical analysis
Association of genetic variants with metabolic parameters
was tested using the non-parametric Mann-Whitney test.
Results of the metabolic studies are depicted as median
and interquartile range.
In silico searches were done at the web site of the National
Center for Biotechnology Information's database SNP
(dbSNP) [26] to determine if any polymorphic sites iden-
tified through our sequencing matched those already
found.
Results
All seven coding exons of the AdipoR1 and AdipoR2 genes
were sequenced in 20 abdominal overweight (BMI 31.0
(29.3–34.6) kg/m2, waist to hip ratio 0.88 (0.83–0.93)),
insulin resistant (HOMA 3.35 (2.52–4.43)), unrelated
German individuals previously recruited for a ran-
domised, placebo-controlled, double-blind crossover
study to determine the effect of telmisartan, an angi-
otensin type-1 receptor blocker with PPAR-γ activating
properties, on glucose and lipid metabolism as well as
inflammatory parameters [24]. DNA sequence analysis of
the AdipoR1 gene revealed one genetic variation not yet
reported in dbSNP (Table 1). In the AdipoR2 gene,
sequencing identified seven variants with two of them
previously reported in dbSNP (Table 1). Interestingly,
three AdipoR2 variants (+795G/A (rs16928751), +870C/
A (Ile290Ile) and +963C/T (rs9805042)) were in perfect
linkage disequilibrium (r2 = 1) and showed a minor allele
frequency of 0.125. Therefore, we decided to focus on this
haplotype to study the impact of genetic variants of
AdipoR2 on glucose, lipid, and inflammatory parameters
in above described subjects.
Table 1: Variations in the seven coding exons of the adiponectin receptor 1 and 2 genes
SNP name SNP location (bp*) Variation (major/minor allele) Minor allele frequency
AdipoR1 Ile321Ile 963 T/C 0.05
AdipoR2 Thr5Thr 15 A/C 0.025
Val182Gly 545 GTG(Val)/GGG(Gly) 0.025
Gln244His 732 CAA(Gln)/CAC(His) 0.025
rs16928751 795 G/A 0.125
Pro272Pro 816 T/C 0.025
Ile290Ile 870 C/A 0.125
rs9805042 963 C/T 0.125
*cDNA base pair location relative to the ATG start siteCardiovascular Diabetology 2006, 5:11 http://www.cardiab.com/content/5/1/11
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Subjects with (AdipoR2-SNP) and without the AdipoR2
SNP cluster (AdipoR2) did not differ in age, BMI, waist-to-
hip ratio, parameters of glucose metabolism, inflamma-
tory parameters, total cholesterol, HDL- and LDL-choles-
terol concentrations (Tables 2,3). However, fasting
triglycerides were consistently significantly lower in sub-
jects with the AdipoR2 SNP cluster at three different time
points (baseline, end of placebo treatment (Figure 1), end
of telmisartan treatment) (Tables 2,3). Furthermore, the
AdipoR2 SNP cluster showed a trend for association with
reduced fasting VLDL-triglyceride and fasting VLDL-cho-
lesterol levels (Table 3). No association was found
between the AdipoR2 SNP cluster and parameters of post-
prandial triglyceride metabolism (Table 3). Interestingly,
the AdipoR2 cluster was associated with significantly
lower adiponectin levels (Table 3, Figure 2) at two differ-
ent timepoints and showed a trend for association with
lower adiponectin levels at one timepoint (Table 2).
Discussion
Our study was designed to test the hypothesis that genetic
variation in the recently identified adiponectin receptor
genes may contribute to insulin resistance, dyslipidemia,
and inflammation. By sequencing all seven coding exons
of the AdipoR1 and AdipoR2 genes in overweight, non-
diabetic, insulin resistant subjects we identified a com-
mon AdipoR2 SNP cluster that was associated with 1)
increased adiponectin levels and 2) decreased fasting trig-
lyceride, VLDL-triglyceride and VLDL-cholesterol levels.
Our study therefore suggests that AdipoR2 may play an
important role in triglyceride/VLDL metabolism. Further-
more, to our knowledge, this is the first study to report an
association between adiponectin receptor gene variants
and plasma adiponectin levels. 
Stefan et al. [27] recently reported the identification of
seven variants of AdipoR2 including the three exonic var-
iants +795G/A, +870C/A and +963C/T referred to as the
AdipoR2 SNP cluster in the present study. By examining
502 German non-diabetic patients, Stefan et al. [27]
showed these variants to be in high linkage disequilib-
rium (r2 ≥ 0.95) with a minor allele frequency of 0.12 con-
sistent with the results of our study. In contrast to our
results, however, Stefan et al. [27] did not find an associa-
tion between these variants and adiponectin or triglycer-
ide levels. This discrepancy may be attributed to different
characteristics of the study populations. Subjects in the
present study showed a markedly higher BMI (means:
31.8 versus 26.4 kg/m2) and insulin resistance index
(HOMA (means): 3.78 versus 1.82), lower adiponectin
levels (means: 2586 versus 10844 ng/ml) and, consider-
ing these differences, most likely higher lipid parameters
(Stefan et al. [27] did not present actual lipid data in their
manuscript).
Fasting triglyceride levels [mg/dl] in subjects without  (AdipoR2) and with the AdipoR2 SNP cluster (AdipoR2- SNP) after 12 weeks of placebo treatment Figure 1
Fasting triglyceride levels [mg/dl] in subjects without 
(AdipoR2) and with the AdipoR2 SNP cluster (AdipoR2-
SNP) after 12 weeks of placebo treatment. Data are pre-
sented as box plot (minimum, 25% quartile, median, 75% 
quartile, maximum).
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Table 2: Baseline characteristics of subjects without (AdipoR2) and with the AdipoR2 SNP cluster (AdipoR2-SNP). Data are presented 
as median and interquartile range.
AdipoR2 AdipoR2-SNP p
n (female/male) 15 (10/5) 5 (3/2)
Age [years] 34 (25–44) 41 (27–53) 0.50
BMI [kg/m2] 30.7 (29.4–34.5) 31.3 (27.3–35.7) 0.87
Waist to hip ratio 0.89 (0.84–0.93) 0.84 (0.78–0.93) 0.50
Fasting plasma glucose [mg/dl] 105 (100–107) 103 (91–113) 0.74
HOMA-index 3.26 (2.44–4.55) 3.43 (2.74–4.31) 0.93
Fasting total cholesterol [mg/dl] 208 (176–229) 188 (150–227) 0.67
Fasting HDL-cholesterol [mg/dl] 52 (40–60) 57 (51–65) 0.31
Fasting LDL-cholesterol [mg/dl] 114 (85–147) 122 (71–142) 0.87
Fasting triglycerides [mg/dl] 176 (118–285) 83 (72–156) 0.01
Adiponectin [ng/ml] 2026 (1477–2470) 3707 (2459–5194) 0.07
HOMA: homeostasis model assessmentCardiovascular Diabetology 2006, 5:11 http://www.cardiab.com/content/5/1/11
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Of course, small numbers of subjects can lead to errone-
ous results and conclusions. However, determination of
metabolic parameters at three different timepoints (0, 12
and 24 weeks) yielded consistent and reproducible
results, thus making random associations unlikely.
Adiponectin acts as an antidiabetic, antiinflammatory,
and antiatherogenic adipokine. Civitarese et al. [23]
reported that in non-diabetic Mexican Americans skeletal
muscle specific expression levels of AdipoR2 but not
AdipoR1 were positively correlated with plasma adi-
ponectin concentrations. Consistent with these data, we
demonstrate that genetic variants of AdipoR2 were associ-
ated with higher plasma adiponectin levels.
Furthermore, we show that these variants were associated
with lower fasting triglyceride, VLDL-triglyceride and
VLDL-cholesterol levels suggesting an important role of
adiponectin receptor 2 in triglyceride/VLDL metabolism.
Staiger et al. [28] demonstrated that AdipoR2 mRNA
expression in human myotubes was only associated with
plasma triglyceride levels, whereas AdipoR1 mRNA
expression was positively correlated with in vivo insulin
and C-peptide concentrations, first phase insulin secre-
tion, plasma triglyceride and cholesterol concentrations.
The lack of association between genetic variants of
AdipoR2 and the triglyceride iAUC in our study suggests
that AdipoR2 does not play a role in chylomicron secre-
tion or hydrolysis. In contrast, association with fasting
triglyceride, VLDL-triglyceride and VLDL-cholesterol con-
centrations would be consistent with a role of AdipoR2 in
the metabolism of endogenous triglyceride-rich lipopro-
teins and possibly postprandial remnant lipoproteins. Ng
et al. [18] previously reported that adiponectin was
inversely associated with plasma triglyceride levels and
directly correlated with VLDL apoB catabolism.
The underlying mechanism resulting in an association of
the AdipoR2 SNP cluster with increased adiponectin lev-
els and decreased triglyceride/VLDL concentrations still
needs to be determined. We hypothesize that these
genetic variants, all of them being silent mutations, are in
Table 3: Parameters of glucose metabolism, lipid metabolism, and inflammation in patients without (AdipoR2) and with the 
adiponectin receptor 2 SNP cluster (AdipoR2-SNP) after 12 weeks of placebo or telmisartan treatment. Data are presented as median 
and interquartile range.
Placebo treatment Telmisartan treatment
AdipoR2 AdipoR2-SNP p AdipoR2 AdipoR2-SNP p
Fasting plasma glucose [mg/dl] 100 (94–105) 103 (100–114) 0.44 99 (94–107) 103 (97–114) 0.53
Fasting insulin [µU/ml] * 11.5 (10.0–20.6) 16.7 (8.1–36.8) 0.55 11.9 (7.6–17.7) 14.0 (7.8–20.0) 0.61
Fasting C-peptide [ng/ml] 2.50 (2.20–2.90) 3.30 (1.90–4.45) 0.55 2.50 (2.20–3.10) 2.70 (1.60–3.35) 0.80
1st phase insulin secretion [pmol/l] * 554 (346–882) 536 (308–814) 1.00 519 (359–698) 565 (452–820) 0.61
2nd phase insulin secretion [pmol/l] * 176 (135–246) 171 (125–235) 0.93 164 (131–207) 185 (151–238) 0.61
Glucose iAUC iv GTT [mg*min/dl]† 1753 (1507–1905) 1818 (1555–3497) 0.47 1600 (1163–1866) 1510 (1326–1914) 0.80
Glucose iAUC oral GTT [mg*h/dl] * 90 (59–111) 79 (74–104) 1.00 86 (48–105) 67 (31–106) 0.50
Insulin iAUC iv GTT [µU*min/ml]† 388 (278–1137) 633 (227–1119) 0.82 407 (297–591) 827 (359–1004) 0.35
Insulin iAUC oral GTT [µU*h/ml] * 110 (71–198) 74 (64–105) 0.27 128 (60–164) 65 (50–156) 0.44
Insulin sensitivity index * -0.07 (-0.25–0.02) -0.04 (-0.26–0.07) 0.50 -0.05 (-0.28–0.07) 0.02 (-0.25–0.05) 1.00
Insulin sensitivity index composite * 2.81 (2.20–4.28) 2.61 (2.10–5.67) 0.93 2.60 (1.84–4.79) 2.62 (2.47–4.66) 0.82
HOMA-index 2.95 (2.56–4.77) 4.28 (2.01–10.0) 0.50 2.87 (1.74–4.40) 3.52 (1.90–5.67) 0.50
HbA1c [%] 5.50 (5.20–5.50) 5.40 (5.25–5.65) 0.93 5.35 (5.30–5.65) 5.30 (5.30–5.70) 0.82
Fasting total cholesterol [mg/dl] 189 (160–224) 177 (146–209) 0.61 182 (164–222) 176 (140–204) 0.67
Fasting HDL-cholesterol [mg/dl] 48 (36–58) 52 (43–60) 0.61 43 (38–56) 49 (44–60) 0.35
Fasting LDL-cholesterol [mg/dl] 100 (81–137) 114 (76–137) 0.93 96 (73–125) 114 (73–137) 0.61
Fasting TG [mg/dl] 162 (123–287) 79 (64–132) 0.01 193 (144–302) 105 (79–113) <0.01
Fasting VLDL-TG [mg/dl] 108 (56–208) 51 (34–91) 0.07 126 (68–228) 59 (38–79) 0.03
Fasting VLDL-cholesterol [mg/dl] 29 (18–42) 8 (8–25) 0.06 32 (15–49) 11 (8–16) 0.03
TG iAUC fat tolerance [mg*h/dl] ‡ 772 (342–1501) 519 (383–1294) 0.75 931 (438–1380) 632 (343–1142) 0.50
VLDL-TG iAUC fat tolerance [mg*h/dl] ‡ 293 (236–611) 238 (87–637) 0.44 317 (149–580) 371 (199–376) 0.75
Chyl-TG iAUC fat tolerance [mg*h/dl] ‡ 529 (301–943) 402 (313–756) 0.96 639 (313–1164) 589 (184–764) 0.39
Adiponectin [ng/ml] 2008 (1425–2413) 3822 (2944–4553) 0.02 2014 (1465–2574) 4573 (2912–4787) 0.04
High sensitivity CRP [mg/l] 6.23 (2.26–8.06) 2.50 (1.54–4.19) 0.10 6.12 (2.85–9.85) 2.25 (1.38–4.81) 0.07
Interleukin-6 [pg/ml] 1.44 (1.11–2.20) 1.17 (0.77–2.11) 0.55 1.46 (1.24–2.52) 1.35 (1.03–2.39) 0.93
Fibrinogen [mg/dl] 418 (366–479) 410 (330–470) 0.61 415 (375–477) 401 (352–475) 0.67
* refers to oral glucose tolerance test; † refers to iv glucose tolerance test; ‡ refers to oral fat tolerance test; HOMA: homeostasis model 
assessment; iAUC: incremental area under the curve; TG: triglyceridesCardiovascular Diabetology 2006, 5:11 http://www.cardiab.com/content/5/1/11
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linkage disequilibrium with another yet unidentified
functional variation in the AdipoR2 gene.
Damcott et al. [29] recently reported that genetic variation
in both adiponectin receptor genes was associated with
type 2 diabetes. However, all these genetic variants were
non-exonic variants and could therefore not be examined
in the present study. Our data did not show any associa-
tion between the AdipoR2 SNP cluster and glucose metab-
olism in overweight, non-diabetic, insulin resistant
patients.
In conclusion, our data provide the first evidence for an
association between variation in the AdipoR2 gene and
plasma adiponectin concentrations as well as triglyceride
and VLDL levels. Larger studies are necessary to confirm
the results of this pilot study.
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